衰老關(guān)鍵蛋白3(FBLN3)等多因子檢測試劑盒(流式熒光發(fā)光法)
Multiplex Assay Kit for Fibulin 3 (FBLN3) ,etc. by FLIA (Flow Luminescence Immunoassay)
EFEMP1; DHRD; DRAD; FBNL; MLVT; MTLV; S1-5; EGF-Containing Fibulin-Like Extracellular Matrix Protein 1; Fibrillin-Like; Extracellular protein S1-5
(注:單次混測多因子不超過8個指標(biāo) )
- 編號LMF422Mu
- 物種Mus musculus (Mouse,小鼠) 相同的名稱,不同的物種。
- 實驗方法雙抗夾心
- 反應(yīng)時長3.5h
- 檢測范圍0.98-1000pg/mL
- 靈敏度最小可檢測劑量小于等于0.327 pg/mL.
- 樣本類型serum, plasma, urine and other biological fluids
- 下載 英文說明書 中文說明書
- 規(guī)格 8指標(biāo)數(shù) 7指標(biāo)數(shù) 6指標(biāo)數(shù) 5指標(biāo)數(shù) 4指標(biāo)數(shù) 3指標(biāo)數(shù) 2指標(biāo)數(shù)1指標(biāo)數(shù)
- 價格 ¥ 2696 ¥ 2799 ¥ 2955 ¥ 3162 ¥ 3370 ¥ 3681 ¥ 4147 計算器 ¥ 5184 添加到價格計算器
- 欲了解實際交易價格和更多情況,請與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
特異性
本試劑盒用于檢測衰老關(guān)鍵蛋白3(FBLN3)等多因子檢測試劑盒(流式熒光發(fā)光法),經(jīng)檢測與其它相似物質(zhì)無明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來源的限制,不可能完成對所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測,因此本試劑盒有可能與未經(jīng)檢測的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的衰老關(guān)鍵蛋白3(FBLN3)等多因子檢測試劑盒(流式熒光發(fā)光法)(加標(biāo)樣品),重復(fù)測定并計算其均值,回收率為測定值與理論值的比率。
樣本 | 回收率范圍(%) | 平均回收率(%) |
serum(n=5) | 78-92 | 86 |
EDTA plasma(n=5) | 78-89 | 82 |
heparin plasma(n=5) | 81-90 | 86 |
精密度
精密度用樣品測定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差:取同批次試劑盒對低、中、高值定值樣本進(jìn)行定量檢測,每份樣本連續(xù)測定20 次,分別計算不同濃度樣本的平均值及SD值。
批間差:選取3個不同批次的試劑盒分別對低、中、高值定值樣本進(jìn)行定量測定,每個樣本使用同一試劑盒重復(fù)測定8次,分別計算不同濃度樣本的平均值及SD值。
批內(nèi)差: CV<10%
批間差: CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的衰老關(guān)鍵蛋白3(FBLN3)等多因子檢測試劑盒(流式熒光發(fā)光法),并倍比稀釋成1:2,1:4,1:8,1:16的待測樣本,線性范圍即為稀釋后樣本中衰老關(guān)鍵蛋白3(FBLN3)等多因子檢測試劑盒(流式熒光發(fā)光法)含量的測定值與理論值的比率。
樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
serum(n=5) | 87-96% | 85-99% | 79-101% | 78-101% |
EDTA plasma(n=5) | 86-96% | 78-93% | 96-104% | 82-102% |
heparin plasma(n=5) | 79-104% | 93-101% | 86-101% | 96-104% |
穩(wěn)定性
經(jīng)測定,試劑盒在有效期內(nèi)按推薦溫度保存,其活性降低率小于5%。
為減小外部因素對試劑盒破壞前后檢測值的影響,實驗室的環(huán)境條件需盡量保持一致,尤其是實驗室內(nèi)溫度、濕度及溫育條件。其次由同一實驗員來進(jìn)行操作可減少人為誤差。
實驗流程
1. 實驗前標(biāo)準(zhǔn)品、試劑及樣本準(zhǔn)備;
2. 加樣(標(biāo)準(zhǔn)品、樣本、磁珠)標(biāo)準(zhǔn)品或樣本100μL及磁珠10μL,
37°C酶標(biāo)板振蕩器孵育90分鐘;
3. 磁吸甩干,加檢測溶液A100μL,37°C酶標(biāo)板振蕩器孵育60分鐘;
4. 磁吸洗板3次;
5. 加檢測溶液B100μL,37°C振動孵育30分鐘;
6. 磁吸洗板3次;
7. 加鞘液100μL,旋渦震蕩2分鐘后讀數(shù)。
實驗原理
將衰老關(guān)鍵蛋白3(FBLN3)等多因子檢測試劑盒(流式熒光發(fā)光法)抗體包被于磁珠,制成固相載體,向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本以及磁珠,其中的衰老關(guān)鍵蛋白3(FBLN3)等多因子檢測試劑盒(流式熒光發(fā)光法)與連接于固相載體上的抗體結(jié)合,然后加入生物素化的衰老關(guān)鍵蛋白3(FBLN3)等多因子檢測試劑盒(流式熒光發(fā)光法)抗體,將未結(jié)合的生物素化抗體洗凈后,加入PE標(biāo)記的親和素,再次徹底洗滌后即可上機讀數(shù)。MFI值和樣品中的衰老關(guān)鍵蛋白3(FBLN3)等多因子檢測試劑盒(流式熒光發(fā)光法)呈正相關(guān)。
贈品
增值服務(wù)
相關(guān)產(chǎn)品
編號 | 適用物種:Mus musculus (Mouse,小鼠) | 應(yīng)用(僅供研究使用,不用于臨床診斷!) |
RPF422Mu01 | 衰老關(guān)鍵蛋白3(FBLN3)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
RPF422Mu02 | 衰老關(guān)鍵蛋白3(FBLN3)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
PAF422Mu01 | 衰老關(guān)鍵蛋白3(FBLN3)多克隆抗體 | WB; IHC; ICC; IP. |
PAF422Mu02 | 衰老關(guān)鍵蛋白3(FBLN3)多克隆抗體 | WB; IHC; ICC; IP. |
SEF422Mu | 衰老關(guān)鍵蛋白3(FBLN3)檢測試劑盒(酶聯(lián)免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
LMF422Mu | 衰老關(guān)鍵蛋白3(FBLN3)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
雜志 | 參考文獻(xiàn) |
1 | Fibulin-3 as a Blood and Effusion Biomarker for Pleural Mesothelioma [PubMed: PMC3761217] |
Anticancer Res. | YKL-40 and mesothelin in the blood of patients with malignant mesothelioma, lung cancer and asbestosis. [Pubmed: 24324091] |
Oncology Reports | Role of fibulin-3 in lung cancer: In vivo and in vitro analyses [Spandidos-publications: Source] |
Current Pulmonology Reports | Discovery of new biomarkers for malignant mesothelioma [Springer:Source] |
United States Patent Application 20140378336 | DIAGNOSIS OF CELL PROLIFERATIVE DISEASES [Freepatentsonline:Source] |
Thorax. | Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma [Pubmed:Pmc4174124] |
Egyptian Journal of Chest Diseases and Tuberculosis | Value of plasma and pleural effusion fibulin-3 levels in the diagnosis of malignant pleural mesothelioma effusions [Pubmed:23050525] |
Radiol Oncol | Fibulin-3 as a biomarker of response to treatment in malignant mesothelioma [PubMed: 26401134] |
British Journal of Cancer | Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis [PubMed: 26263483] |
J Thorac Oncol. | Plasma Biomarker Enrichment of Clinical Prognostic Indices in Malignant Pleural Mesothelioma. [Pubmed:26903362] |
BMJ Open | Diagnostic and Prognostic Biomarkers in the Rational Assessment of Mesothelioma (DIAPHRAGM) study: protocol of a prospective, multicentre, observational study [pubmed:27884852] |
25 | HMGB1 and its hyperacetylated isoform are sensitive and specific serum biomarkers to detect asbestos exposure and to identify mesothelioma patients [pubmed:26733616] |
BMJ Journals | Diagnostic and Prognostic Biomarkers in the Rational Assessment of Mesothelioma (DIAPHRAGM) study: protocol of a prospective, multicentre, observational … [e013324.abstract] |
Anticancer Res. | Comparison of the Diagnostic Performance of Fibulin-3 and Mesothelin in Patients with Pleural Effusions from Malignant Mesothelioma. [pubmed:28314308] |
Dis Markers. | A Novel Panel of Serum Biomarkers for MPM Diagnosis. [pubmed:28348450] |
The Knee | Association of fibulin-3 concentrations with the presence and severity of knee osteoarthritis: A cross-sectional study [pubmed:29195846] |
Disease markers | Plasma Fibulin-3 as a Potential Biomarker for Patients with Asbestos-Related Diseases in the Han Population [pubmed:29200597] |
Molecular?Medicine?Reports | Placental protein 14 as a potential biomarker for diagnosis of preterm premature rupture of membranes [Pubmed:29749501] |
Oncotarget | The matrix protein Fibulin-3 promotes KISS1R induced triple negative breast cancer cell invasion [Pubmed:30046386] |
Advances in?Clinical?and Experimental?Medicine | Fibulin-3 and other cartilage metabolism biomarkers in relationship to calprotectin (MRP8/14) and disease activity in rheumatoid arthritis patients treated with?… [68362.pdf] |
PLoS One | Prediction of pneumoconiosis by serum and urinary biomarkers in workers exposed to asbestos-contaminated minerals [Pubmed: 30946771] |